Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports
$16,500.00   |  '

Immune-Mediated Inflammatory Myopathies | Executive Insights | US | 2020

Login to access report north_east
Buy report north_east

Immune-mediated inflammatory myopathies (IMIMs) are rare disorders that encompass multiple subtypes including dermatomyositis, immune-mediated necrotizing myopathy or necrotizing autoimmune myopathy (NAM), and alpha-synthetase syndrome. While their pathogenesis is unclear, research is rapidly uncovering novel targets and disease markers. The management of these disorders is evolving as autoantibody markers are linked to patient comorbidities, as patient heterogeneity increasingly comes into focus, and as novel drugs progress through the pipeline. Potential line extensions for branded biologics are also nearing final stages of the pipeline. With an increasingly crowded pipeline and a limited number of patients and multiple treating physicians, which therapies are poised to dominate these niche markets?

QUESTIONS ANSWERED

· What is the diagnosed prevalence of dermatomyositis, of immune-mediated necrotizing myopathy, and of the alpha-synthetase syndrome?

· How are each of the subpopulations treated today?

· What are the key areas of unmet need and opportunity in the management of immune-mediated inflammatory myopathies?

· What is the potential impact of new launches and how will these therapies affect future opportunity in the different subtypes of immune-mediated inflammatory myopathies?

· What are the key drivers and limiters of the market today and in the future?

PRODUCT DESCRIPTION

Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Buy report north_east
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east